Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment

Table 3 Effect of 3% hypertonic saline on urinary parameters in 22 healthy subjects treated with bendroflumethiazide or amiloride

Periods	Baseline	Infusion	Post infusion			PGLM RM
	0-90 min	90-150 min	150-180 min	180-210 min	210-240 min
CH2O < 0.001
BFTZ	3.1 ± 1.6a	-0.2 ± 0.5d	-1.6 ± 0.6d	-1.6 ± 0.7d	-0.6 ± 1.6d
Amiloride	3.7 ± 0.9	-0.6 ± 0.7d	-2.1 ± 0.6d	-2.4 ± 0.8d	-1.4 ± 1.7d
Placebo	4.4 ± 1.1	-0.6 ± 0.6d	1.8 ± 0.7d	-2.5 ± 1.0d	-2.0 ± 0.5d
PGLM between subjects 0.061
PANOVA	0.006	NS	NS	0.001	0.007
UO (mL/min) 0.029
BFTZ	6.1 ± 1.6	2.6 ± 0.6d	1.4 ± 0.5d	1.7 ± 1.0d	2.7 ± 1.9d
Amiloride	6.8 ± 1.3	2.5 ± 0.6d	1.6 ± 0.5d	2.0 ± 0.7d	3.2 ± 1.2d
Placebo	7.3 ± 1.2	2.3 ± 0.9d	1.7 ± 0.8d	2.2 ± 1.2d	2.4 ± 1.1d
PGLM between subjects 0.245
PANOVA	0.019	NS	NS	NS	NS
u-Na (mmol/min) 0.001
BFTZ	1.4 ± 0.4	1.7 ± 0.4b	1.9 ± 0.7b	2.1 ± 0.6d	2.0 ± 0.6b
Amiloride	1.6 ± 0.5	2.0 ± 0.7	2.5 ± 1.0b	2.9 ± 1.2d	3.0 ± 1.0d
Placebo	1.3 ± 0.3	1.9 ± 1.1a	2.5 ± 1.3b	3.3 ± 1.7d	3.0 ± 1.0d
PGLM between subjects 0.020
PANOVA	0.028	NS	NS	0.007	<0.001
FENa (%) < 0.001
BFTZ	1.5 ± 0.4	1.8 ± 0.5a	2.0 ± 0.6b	2.2 ±0.6d	2.1 ± 0.6d
Amiloride	1.8 ± 0.6	2.1 ± 0.6a	2.6 ± 1.0b	2.9 ± 1.2d	3.0 ± 1.1d
Placebo	1.4 ± 0.4	2.1 ± 1.0b	2.7 ± 1.2d	3.0 ± 1.1d	3.1 ± 1.1d
PGLM between subjects 0.036
PANOVA	0.022	NS	NS	0.019	0.001
u-K (mmol/min)
BFTZ	20.3 ± 6.7	17.7 ± 5.3	15.8 ± 4.4b	14.2 ± 5.6b	13.3 ± 6.3b	< 0.001
Amiloride	18.5 ± 8.4	15.7 ± 9.3	18.6 ± 11.1	22.4 ± 12.0	23.3 ± 10.2a
Placebo	22.3 ± 9.3	15.6 ± 6.9d	16.4 ± 8.5a	22.3 ± 12.3	20.4 ± 7.9
PGLM between subjects 0.255
PANOVA	NS	NS	NS	0.015	0.001
FEK (%)
BFTZ	21.7 ± 7.4	20.0 ± 6.6	16.1 ± 4.8b	15.0 ± 5.9b	14.4 ± 6.9b	< 0.001
Amiloride	20.8 ± 9.8	18.7 ± 10.8	20.5 ± 12.0	23.6 ± 12.4	25.0 ± 11.0a
Placebo	23.7 ± 9.3	18.1 ± 8.2b	17.5 ± 8.9a	20.6 ± 9.9	21.4 ± 8.8
PGLM between subjects 0.254
PANOVA	NS	NS	NS	0.018	0.001
51Cr-EDTA (mL/min per 1.73m2) 0.271
BFTZ	92.1 ± 10.8	91.3 ± 11.9	96.0 ± 16.7	96.9 ± 16.8	96.5 ± 21.2
Amiloride	92.7 ± 13.7	93.2 ± 12.8	94.1 ± 12.1	96.7 ± 14.1	100.2 ± 15.6
Placebo	96.5 ± 9.5	90.0 ± 13.3	94.7 ± 15.1	102.4 ± 14.3	98.1 ± 15.9
PGLM between subjects 0.887

Free water clearance (C_H2O), urinary output (OU), excretion of sodium (u-Na) and fractional excretion of sodium (FENa), urinary excretion of potassium (u-K) and fractional excretion of potassium (FEK) and

⁵¹Cr-EDTA clearance in a randomized, placebo-controlled, crossover study of 23 healthy subjects. Values are mean ± SD. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as between subjects factor. One-way ANOVA was performed when differences were found between interventions. Post hoc Bonferroni correction was used for multiple comparisons of post infusion periods to baseline within each treatment group.

^aP < 0.05;

^bP < 0.01;

^dP <0.001.